Abstract: A system for unsupervised deep representation learning based on image translation is provided. The system includes an image translation transformation module used for performing a random translation transformation on an image and generating an auxiliary label; an image mask module connected with the image translation transformation module and used for applying a mask to the image after translation transformation; a deep neural network connected with the image mask module and used for predicting an actual auxiliary label of the image after the mask is applied and learning the deep representation of the image; a regression loss function module connected with the deep neural network and used for updating parameters of the deep neural network based on a loss function; and a feature extraction module connected with the deep neural network and used for extracting the representation of the image.

Abstract: A multi-modal adaptive fusion deep clustering model based on an auto-encoder includes an encoder structure, a multi-modal adaptive fusion layer, a decoder structure and a deep embedding clustering layer. The encoder is configured to enable a dataset to be respectively subjected to three types of nonlinear mappings of the auto-encoder, a convolutional auto-encoder and a convolutional variational auto-encoder to obtain potential features, respectively. The multi-modal adaptive feature fusion layer is configured to fuse the potential features into a common subspace in an adaptive spatial feature fusion mode to obtain a fused feature. The decoder is configured to decode the fused feature by using a structure symmetrical to the encoder to obtain a decoded reconstructed dataset. The deep embedding clustering layer is configured to cluster the fused feature Z and obtain a final accuracy ACC by comparing a clustering result with a true label.

Abstract: Positive allosteric modulators (PAMs) of Mas-related G protein-coupled receptor X1 (MRGPRX1) and their use for treating neuropathic pain is disclosed.

Abstract: The present invention relates to cells and methods for detecting compounds that affect G protein coupled receptor mediated conditions. The invention also relates to methods for treating adverse drug reactions, autoimmune disorders, and pruritus.

Abstract: The present invention relates to cells and methods for detecting compounds that affect G protein coupled receptor mediated conditions. The invention also relates to methods for treating adverse drug reactions, autoimmune disorders, and pruritus.

Abstract: The present invention features compositions of Tmem100 peptides and variants thereof, and their use in treating or preventing diseases or conditions.

Abstract: The present invention features compositions of Tmem100 peptides and variants thereof, and their use in treating or preventing diseases or conditions.

Abstract: The present invention relates to cells and methods for detecting compounds that induce a pseudo-allergic-type reaction and methods for reducing the severity of a pseudo-allergic-type reaction.

Abstract: The present invention relates to cells and methods for detecting compounds that induce a pseudo-allergic-type reaction and methods for reducing the severity of a pseudo-allergic-type reaction.

Abstract: The present invention relates to cells and methods for detecting compounds that affect G protein coupled receptor mediated conditions. The invention also relates to methods for treating adverse drug reactions, autoimmune disorders, and pruritus.

Abstract: The invention features therapeutic compositions comprising agents useful for the treatment or prevention of pruritis, and methods useful for identifying such agents.

Abstract: The present invention features compositions of Tmem100 peptides and variants thereof, and their use in treating or preventing diseases or conditions.

Abstract: The invention features therapeutic compositions comprising agents useful for the treatment or prevention of pruritis, and methods useful for identifying such agents.

Abstract: The present invention relates to cells and methods for detecting compounds that induce a pseudo-allergic-type reaction and methods for reducing the severity of a pseudo-allergic-type reaction.

Abstract: The invention relates generally to novel genes expressed in normal but not Neurogenin-1-deficient animals. The invention relates specifically to a novel family of G protein-coupled receptors and a novel family of two-transmembrane segment proteins that are expressed in dorsal root ganglia, and a method of screening for genes specifically expressed in nociceptive sensory neurons.

Abstract: The invention features therapeutic compositions comprising agents useful for the treatment or prevention of pruritis, and methods useful for identifying such agents.

Abstract: The invention features therapeutic compositions comprising agents useful for the treatment or prevention of pruritis, and methods useful for identifying such agents.

Abstract: The present application provides methods and compositions that can be used to treat persistent pain and to identify compounds that can be used for treating persistent pain. More specifically, agonists of members of the Mrgpr receptor family, particularly agonists of MrgprX1, can identified and screened for use in treating persistent pain, such as pain caused by inflammation or nerve injury.

Abstract: The invention relates generally to novel genes expressed in normal but not neurogenin-1-deficient animals. The invention relates specifically to a novel family of G protein-coupled receptors and a novel family of two-transmembrane segment proteins that are expressed in dorsal root ganglia, and a method of screening for genes specifically expressed in nociceptive sensory neurons.

Abstract: The invention relates generally to novel genes expressed in normal but not Neurogenin-1-deficient animals. The invention relates specifically to a novel family of G protein-coupled receptors and a novel family of two-transmembrane segment proteins that are expressed in dorsal root ganglia, and a method of screening for genes specifically expressed in nociceptive sensory neurons.